The content on this site is intended for healthcare professionals only
Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refrac...
Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
21 Sep 2021
New MM patients with high levels of circulating tumour cells distinguished by in...
Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands
21 Sep 2021
Novel therapies in multiple myeloma
Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
20 Sep 2021
Disparities in myeloma: Closing the gap
Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA
20 Sep 2021
CARTITUDE-2: Ciltacabtagene autoleucel in patients with progressive multiple mye...
Prof Adam Cohen - University of Pennsylvania, Philadelphia, USA
19 Sep 2021
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL am...
Dr Shaji Kumar - Mayo Clinic, Rochester, USA
19 Sep 2021
B-cell maturation antigen targeted CD3-engaging bispecific molecule for relapsed...
Prof Bhagirathbhai Dholaria - Vanderbilt University Medical Center, Nashville, U...
18 Sep 2021
Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethaso...
Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain
14 Sep 2021
Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or car...
Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA
14 Sep 2021
Should every transplant eligible NDMM patient receive a transplant?
Prof Morie Gertz - Mayo Clinic, Rochester, USA
14 Sep 2021
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
10 Sep 2021
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-ta...
Dr Oliver Van Oekelen - Icahn School of Medicine at Mount Sinai, New York City, ...
10 Sep 2021
